Unbound MEDLINE

A mechanism-based classification of dermatologic reactions to biologic agents used in the treatment of cutaneous disease: Part 1. Dermatitis : contact, atopic, occupational, drug : official journal of the American Contact Dermatitis Society, North American Contact Dermatitis Group [Dermatitis] Journal article

 
TitleA mechanism-based classification of dermatologic reactions to biologic agents used in the treatment of cutaneous disease: Part 1.
Author(s)Bremmer M, Deng A, Gaspari AA 
InstitutionDepartment of Dermatology, University of Maryland, Baltimore, MD 21201-1734, USA.
SourceDermatitis 2009 Aug; 20(4):182-92.
AbstractBiologic therapies are an efficacious new method of controlling a number of chronic conditions. Data regarding these medications continues to emerge, giving clinicians a greater understanding of their side effects profiles. The biologic agents used in dermatology, particularly the tumor necrosis factor-alpha inhibitors, have a number of varied dermatologic side effects. In this two-part article, we perform a review of literature regarding the cutaneous side effects of infliximab, etanercept, adalimumab, rituximab, efalizumab, and alefacept. In Part 1, we will discuss cutaneous infections, malignancy, rebound phenomenon, eczema, atopic dermatitis, lichenoid reactions, granulomatous disease, pruritus, acne, and progressive multifocal leukoencephalopathy.
Languageeng
Pub Type(s)Journal Article
PubMed ID19804694
  
Advertise on this site.